Multicenter Open-label, Phase II Trial, to Evaluate the Efficacy and Safety of Nal-IRI for Progressing Brain Metastases in Patients With HER2-negative Breast Cancer (The Phenomenal Study)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 12 Dec 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Irinotecan (Primary)
Indications Advanced breast cancer; Brain metastases; HER2 negative breast cancer
Focus Therapeutic Use
Acronyms PHENOMENAL
Sponsors Medica Scientia Innovation Research

05 Dec 2024 According to MEDSIR media release, the company were presented the data from this study at San Antonio Breast Cancer Symposium 2024.
15 Apr 2024 Planned End Date changed from 31 Mar 2024 to 2 Jun 2025.
03 Apr 2024 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com